BR112022000207A2 - Formas cristalinas de inibidores de calicreína plasmática - Google Patents

Formas cristalinas de inibidores de calicreína plasmática

Info

Publication number
BR112022000207A2
BR112022000207A2 BR112022000207A BR112022000207A BR112022000207A2 BR 112022000207 A2 BR112022000207 A2 BR 112022000207A2 BR 112022000207 A BR112022000207 A BR 112022000207A BR 112022000207 A BR112022000207 A BR 112022000207A BR 112022000207 A2 BR112022000207 A2 BR 112022000207A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
plasma kallikrein
kallikrein inhibitors
benzyl
same
Prior art date
Application number
BR112022000207A
Other languages
English (en)
Inventor
Jamie Marshall
Scott Northen Julian
Sukanto Sinha
Tamie Chilcote
Original Assignee
Activesite Pharmaceuticals Inc
Rezolute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activesite Pharmaceuticals Inc, Rezolute Inc filed Critical Activesite Pharmaceuticals Inc
Publication of BR112022000207A2 publication Critical patent/BR112022000207A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

formas cristalinas de inibidores de calicreína plasmática. a presente invenção refere-se a formas cristalinas puras de acetato de 1-benzil-n-(4-carbamimidoil-benzil)-1h-pirazol-4-carboxamida e a uma forma amorfa, composições farmacêuticas das mesmas e métodos para a produção das mesmas.
BR112022000207A 2019-07-08 2020-07-07 Formas cristalinas de inibidores de calicreína plasmática BR112022000207A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871517P 2019-07-08 2019-07-08
PCT/US2020/040955 WO2021007189A1 (en) 2019-07-08 2020-07-07 Crystalline forms of plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
BR112022000207A2 true BR112022000207A2 (pt) 2022-05-17

Family

ID=74101877

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000207A BR112022000207A2 (pt) 2019-07-08 2020-07-07 Formas cristalinas de inibidores de calicreína plasmática

Country Status (11)

Country Link
US (2) US11306061B2 (pt)
EP (1) EP3996707A4 (pt)
JP (1) JP2022539856A (pt)
KR (1) KR20220057523A (pt)
CN (1) CN114867477A (pt)
AU (1) AU2020310859A1 (pt)
BR (1) BR112022000207A2 (pt)
CA (1) CA3145298A1 (pt)
IL (1) IL289214A (pt)
MX (1) MX2022000311A (pt)
WO (1) WO2021007189A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2007281220B2 (en) * 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2259679A4 (en) * 2008-01-31 2011-09-14 Joslin Diabetes Ct METHOD FOR THE TREATMENT OF CALLIQUE CLEANING DISORDERS
US8259170B2 (en) * 2009-08-24 2012-09-04 Cellomics, Inc. Integrated calibration sample bay for fluorescence readers
CN107848979A (zh) * 2015-05-21 2018-03-27 苏州晶云药物科技有限公司 乐伐替尼甲磺酸盐的新晶型及其制备方法
GB201719881D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof

Also Published As

Publication number Publication date
AU2020310859A1 (en) 2022-01-27
EP3996707A4 (en) 2023-02-22
US11306061B2 (en) 2022-04-19
US20220380315A1 (en) 2022-12-01
CN114867477A (zh) 2022-08-05
KR20220057523A (ko) 2022-05-09
IL289214A (en) 2022-02-01
MX2022000311A (es) 2022-04-20
EP3996707A1 (en) 2022-05-18
JP2022539856A (ja) 2022-09-13
CA3145298A1 (en) 2021-01-14
WO2021007189A1 (en) 2021-01-14
US20210009525A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
MX2022007432A (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino.
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
CO2017003833A2 (es) Pirimidinonas como inhibidores del factor xia
EA201790884A8 (ru) 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
WO2020141419A3 (en) Novel salts and polymorphic form of bempedoic acid
EA201790881A8 (ru) 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
MX2017006567A (es) Esteroides 6.alfa.-alquil-6,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
EA201790879A1 (ru) 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
MY181641A (en) Amino pyran ring derivative and composition and use thereof
PH12017500737B1 (en) Kcnq2-5 channel activator
BR112016010862A8 (pt) formas mórficas de ésteres de hexadeciloxipropil-fosfonato, seu método de preparo e composição compreendendo a dita forma mórfica
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
WO2015102022A3 (en) An improved process for the preparation of abiraterone acetate
BR112022000207A2 (pt) Formas cristalinas de inibidores de calicreína plasmática
EA201391173A1 (ru) Изоксазолидиновые производные
ECSP13012459A (es) Valsartan altamente cristalino
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
WO2014145035A8 (en) Methods of making cancer compositions
MX2019005785A (es) Proceso para la purificacion de 1-(4-clorofenil)pirazol-3-ol.
NZ705902A (en) Isoxazolidine derivatives
IL283902A (en) Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
MX2020012065A (es) Compuestos de ciclopentano.